長江生命科技(00775.HK):定期審視及調配資源支持科研項目 供應檢測試劑非一項生意
長江生命科技(00775.HK)今日(14日)舉行股東週年大會,對於股東提問短期內是否以醫藥科研為投資重點,及可會繼續進行其他併購活動,公司回應指其經營模式是以多元化業務組合奠立良好的收益、現金流及發展根基,從而推動醫藥研究穩步向前。公司將定期審視及調配適當資源,致力支持科研項目。隨著醫藥研發持續越來越快,相關之財務支援或將有所增加,兩者之間要取平衡。
至於會否分拆黑色素瘤疫苗項目上市,公司稱對任何投資及業務發展機遇均會進行研究,不可抹殺此可能性,但暫時不是優先。而現時大部份之資金用於黑色素瘤疫苗第三階段臨床試驗,該試驗的進展順利。公司正考慮調配資源以開展痛楚舒緩藥物Halneuron的第三階段臨床試驗,務求支持此項將維持數年的研究能順利完成。
另外,COVID-19檢測試劑盒銷情方面,公司指,供應檢測試劑並非一項生意,只是希望於疫情下幫助大眾。而在疫情之下,市場對能增強免疫的保健品如維他命C等都有需求。
派息方面,長江生命科技指對於生物科技公司而言,派息要在公司未來前景及股東回報之間取得平衡。如將賺到的錢放多些在科研之上,能推動研發快些有成果,有助公司長遠發展;但如把盈利分派多些給股東,雖然短期回報是正面,但會影響公司的科研進度,對於長遠前景未必是好事。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.